南新制药：市场环境或行业政策未发生重大调整，内部生产经营秩序正常

Core Viewpoint - The company has experienced a significant stock price decline, with a cumulative drop of 70% over 30 consecutive trading days, indicating severe abnormal trading fluctuations [1] Group 1: Stock Performance - The company's stock price has deviated significantly, with a cumulative decline of 70% over the last 30 trading days, which is classified as severe abnormal trading behavior [1] - The company has conducted a self-examination and confirmed that its daily operations are normal, with no major changes occurring [1] Group 2: Business Operations - There have been no significant changes in the market environment or industry policies affecting the company [1] - The internal production and operational order of the company remains normal as of the announcement date [1] Group 3: Corporate Actions - The company has signed a "Termination Agreement" with three other pharmaceutical companies, agreeing to terminate the planned major asset restructuring [1] - The involved parties have reached a consensus to halt the major asset restructuring process [1]